Terry Rich, who played a pivotal role in the turnaround of Alphatec Spine, has been named president of Global Spine at RTI Surgical Holdings, Inc. In addition, Olivier Visa has been promoted to president of Global OEM.
RTI Surgical Beefs Up With Two Top Industry Vets

Mr. Rich, as a director and CEO of Alphatec Spine, strengthened the organization’s competencies and, according to RTI Surgical, redirected the portfolio with 12 new products and laid the foundation for focused innovation and growth. Before joining Alphatec Spine, Rich was president of Upper Extremities at Wright Medical Group, N.V. Rich had previously held sales leadership positions at Tornier, NuVasive and DePuy Spine.
“This is an important appointment that adds a globally recognized leader to the helm of our spine segment at RTI,” said Camille Farhat, company president and CEO. “Terry has a deep commitment to growth and innovation, as well as exceptional relationships with clinical thought leaders in our market. Our spine business is in the early stages of what we believe is a longer-term transformation with tremendous opportunities ahead. We believe Terry’s leadership will help accelerate the execution of our Novel Therapies commercial channel and multiple product launches planned for 2020.”
According to RTI, “Visa joined RTI in October 2017 as vice president of OEM and has spearheaded the positive performance of this business segment within RTI. Under his leadership, the OEM segment has earned a solid market position serving leading medical technology companies that operate in a diverse set of end markets with attractive growth profiles. Over the past two years the business has returned to growth, driven operational excellence and delivered significant predictable recurring EBITDA.”
Terry Rich told OTW, “I am thrilled to be joining RTI Surgical as the leader of the global spine business with a heightened focus on strengthening our commercial channels, globalizing our portfolio, advancing our product development pipeline and integrating new technologies to enable physician partners to deliver better outcomes. My immediate focus is getting up to speed on our teams, key customers, operating plan, current portfolio, R&D pipeline and international markets. I am eager to meet folks face-to-face over the next few weeks. This is an exciting time for our spine business as we are gaining momentum and have much to look forward to in 2020.”
Olivier Visa, who will be RTI’s new president of Global OEM, told OTW that, “Going forward, our priorities center around improving customer intimacy and pursuing focused innovation of products and services. We have tremendous opportunity to leverage our deep expertise in design, private label product development, manufacturing and processing to expand our customer partnerships and fulfill our deep product pipeline.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.